Search

Your search keyword '"BULGARELLI S"' showing total 75 results
Start Over Author "BULGARELLI S"
75 results on '"BULGARELLI S"'

2. Consensus statements on vaccination in patients with haemophilia—Results from the Italian haemophilia and vaccinations (HEVA) project

Author

Santagostino E., Riva A., Cesaro S., Esposito S., Matino D., Mazzucchelli R. I., Molinari, Angelo Claudio, Mura R., Notarangelo L. D., Tagliaferri A., Di Minno G., Clerici M., Ambaglio C., Brigida Aru A., Baldacci E., Barillari G., Basso M., Bernasconi S., Bertamino M., Bertoni E., Biasoli C., Federica Biguzzi E., Bonetti E., Borchiellini A., Bulgarelli S., Cabibbo S., Cantori I., Castaman G., Castiglia P., Coluccia A., Coppetelli U., Coppola A., Cultrera D., De Candia E., Delios G., Di Gennaro L., Di Gregorio P., Di Minno M., Dragani A., Pietro Ettorre C., Franchini M., Galli M., Gallo G., Giordano P., Giuffrida G., Iannaccaro P., Lassandro G., Lazzareschi I., Linari S., Luciani M., Macchi S., Malcangi G., Malizia R., Marietta M., Marino R., Massoud M., Gabriella Mazzucconi M., Milan M., Morfini M., Napolitano M., Pasca S., Pedrazzi P., Peyvandi F. A., Piscitelli L., Pollio B., Preti P., Quintavalle G., Radossi P., Raso S., Ricca I., Rocino A., Santoro C., Carlotta Santoro R., Sarolo L., Schiavoni M., Schiavulli M., Sciancalepore P., Luisa Serino M., Mario Siragusa S., Sottilotta G., Svahn J., Valdre L., Cristina Vedovati M., Zanon E., Santagostino, E., Riva, A., Cesaro, S., Esposito, S., Matino, D., Mazzucchelli, R. I., Molinari, Angelo Claudio, Mura, R., Notarangelo, L. D., Tagliaferri, A., Di Minno, G., Clerici, M., Ambaglio, C., Brigida Aru, A., Baldacci, E., Barillari, G., Basso, M., Bernasconi, S., Bertamino, M., Bertoni, E., Biasoli, C., Federica Biguzzi, E., Bonetti, E., Borchiellini, A., Bulgarelli, S., Cabibbo, S., Cantori, I., Castaman, G., Castiglia, P., Coluccia, A., Coppetelli, U., Coppola, A., Cultrera, D., De Candia, E., Delios, G., Di Gennaro, L., Di Gregorio, P., Di Minno, M., Dragani, A., Pietro Ettorre, C., Franchini, M., Galli, M., Gallo, G., Giordano, P., Giuffrida, G., Iannaccaro, P., Lassandro, G., Lazzareschi, I., Linari, S., Luciani, M., Macchi, S., Malcangi, G., Malizia, R., Marietta, M., Marino, R., Massoud, M., Gabriella Mazzucconi, M., Milan, M., Morfini, M., Napolitano, M., Pasca, S., Pedrazzi, P., Peyvandi, F. A., Piscitelli, L., Pollio, B., Preti, P., Quintavalle, G., Radossi, P., Raso, S., Ricca, I., Rocino, A., Santoro, C., Carlotta Santoro, R., Sarolo, L., Schiavoni, M., Schiavulli, M., Sciancalepore, P., Luisa Serino, M., Mario Siragusa, S., Sottilotta, G., Svahn, J., Valdre, L., Cristina Vedovati, M., and Zanon, E.

Subjects
Adult, medicine.medical_specialty, Consensus, Delphi Technique, Vaccination schedule, Delphi method, haemophilia, 030204 cardiovascular system & hematology, Hemophilia A, Haemophilia, immunization, Hemophilia B, bleeding disorder, factor VIII inhibitor, vaccination, Child, Evidence-Based Medicine, Humans, Italy, Vaccination, 03 medical and health sciences, 0302 clinical medicine, Vaccine administration, Medicine, In patient, Clinical Haemophilia, Genetics (clinical), business.industry, Original Articles, Hematology, General Medicine, Evidence-based medicine, medicine.disease, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, Immunization, Family medicine, Original Article, business, 030215 immunology
Abstract

Vaccination against communicable diseases is crucial for disease prevention, but this practice poses challenges to healthcare professionals in patients with haemophilia. Poor knowledge of the vaccination requirements for these patients and safety concerns often result in vaccination delay or avoidance. In order to address this issue, a panel of 11 Italian haemophilia and immunization experts conducted a Delphi consensus process to identify the main concerns regarding the safe use of vaccines in patients with haemophilia. The consensus was based on a literature search of the available evidence, which was used by the experts to design 27 consensus statements. A group of clinicians then rated these statements using the 5‐point Likert‐type scale (1 = strongly disagree; 5 = strongly agree). The main issues identified by the expert panel included vaccination schedule for haemophilic patients; protocol and optimal route of vaccine administration; vaccination of haemophilic patients with antibodies inhibiting coagulation factor VIII (inhibitors); and vaccination and risk of inhibitor development. This manuscript discusses these controversial areas in detail supported by the available literature evidence and provides evidence‐ and consensus‐based recommendations. Overall, participants agreed on most statements, except those addressing the potential role of vaccination in inhibitor formation. Participants agreed that patients with haemophilia should receive vaccinations according to the institutional schedule for individuals without bleeding disorders; however, vaccination of patients with haemophilia requires comprehensive planning, taking into account disease severity, type and route of vaccination, and bleeding risk. Data also suggest vaccination timing does not need to take into consideration when the patient received factor VIII replacement.

Published
2019

3. Consensus statements on vaccination in patients with haemophilia—Results from the Italian haemophilia and vaccinations (HEVA) project

Author

Santagostino, E., Riva, A., Cesaro, S., Esposito, S., Matino, D., Mazzucchelli, R. I., Molinari, A. C., Mura, R., Notarangelo, L. D., Tagliaferri, A., Di Minno, G., Clerici, M., Ambaglio, C., Brigida Aru, A., Baldacci, E., Barillari, G., Basso, M., Bernasconi, S., Bertamino, M., Bertoni, E., Biasoli, C., Federica Biguzzi, E., Bonetti, E., Borchiellini, A., Bulgarelli, S., Cabibbo, S., Cantori, I., Castaman, G., Castiglia, P., Coluccia, A., Coppetelli, U., Coppola, A., Cultrera, D., De Candia, Erica, Delios, G., Di Gennaro, L., Di Gregorio, P., Di Minno, M., Dragani, A., Pietro Ettorre, C., Franchini, M., Galli, M., Gallo, G., Giordano, P., Giuffrida, G., Iannaccaro, P., Lassandro, G., Lazzareschi, Ilaria, Linari, S., Luciani, M., Macchi, S., Malcangi, G., Malizia, R., Marietta, M., Marino, R., Massoud, M., Gabriella Mazzucconi, M., Milan, M., Morfini, M., Napolitano, M., Pasca, S., Pedrazzi, P., Peyvandi, F. A., Piscitelli, L., Pollio, B., Preti, P., Quintavalle, G., Radossi, P., Raso, S., Ricca, I., Rocino, A., Santoro, C., Carlotta Santoro, R., Sarolo, L., Schiavoni, M., Schiavulli, M., Sciancalepore, P., Luisa Serino, M., Mario Siragusa, S., Sottilotta, G., Svahn, J., Valdre, L., Cristina Vedovati, M., Zanon, E., De Candia E. (ORCID:0000-0003-0942-2819), Lazzareschi I. (ORCID:0000-0001-7221-2983), Santagostino, E., Riva, A., Cesaro, S., Esposito, S., Matino, D., Mazzucchelli, R. I., Molinari, A. C., Mura, R., Notarangelo, L. D., Tagliaferri, A., Di Minno, G., Clerici, M., Ambaglio, C., Brigida Aru, A., Baldacci, E., Barillari, G., Basso, M., Bernasconi, S., Bertamino, M., Bertoni, E., Biasoli, C., Federica Biguzzi, E., Bonetti, E., Borchiellini, A., Bulgarelli, S., Cabibbo, S., Cantori, I., Castaman, G., Castiglia, P., Coluccia, A., Coppetelli, U., Coppola, A., Cultrera, D., De Candia, Erica, Delios, G., Di Gennaro, L., Di Gregorio, P., Di Minno, M., Dragani, A., Pietro Ettorre, C., Franchini, M., Galli, M., Gallo, G., Giordano, P., Giuffrida, G., Iannaccaro, P., Lassandro, G., Lazzareschi, Ilaria, Linari, S., Luciani, M., Macchi, S., Malcangi, G., Malizia, R., Marietta, M., Marino, R., Massoud, M., Gabriella Mazzucconi, M., Milan, M., Morfini, M., Napolitano, M., Pasca, S., Pedrazzi, P., Peyvandi, F. A., Piscitelli, L., Pollio, B., Preti, P., Quintavalle, G., Radossi, P., Raso, S., Ricca, I., Rocino, A., Santoro, C., Carlotta Santoro, R., Sarolo, L., Schiavoni, M., Schiavulli, M., Sciancalepore, P., Luisa Serino, M., Mario Siragusa, S., Sottilotta, G., Svahn, J., Valdre, L., Cristina Vedovati, M., Zanon, E., De Candia E. (ORCID:0000-0003-0942-2819), and Lazzareschi I. (ORCID:0000-0001-7221-2983)

Abstract

Vaccination against communicable diseases is crucial for disease prevention, but this practice poses challenges to healthcare professionals in patients with haemophilia. Poor knowledge of the vaccination requirements for these patients and safety concerns often result in vaccination delay or avoidance. In order to address this issue, a panel of 11 Italian haemophilia and immunization experts conducted a Delphi consensus process to identify the main concerns regarding the safe use of vaccines in patients with haemophilia. The consensus was based on a literature search of the available evidence, which was used by the experts to design 27 consensus statements. A group of clinicians then rated these statements using the 5-point Likert-type scale (1 = strongly disagree; 5 = strongly agree). The main issues identified by the expert panel included vaccination schedule for haemophilic patients; protocol and optimal route of vaccine administration; vaccination of haemophilic patients with antibodies inhibiting coagulation factor VIII (inhibitors); and vaccination and risk of inhibitor development. This manuscript discusses these controversial areas in detail supported by the available literature evidence and provides evidence- and consensus-based recommendations. Overall, participants agreed on most statements, except those addressing the potential role of vaccination in inhibitor formation. Participants agreed that patients with haemophilia should receive vaccinations according to the institutional schedule for individuals without bleeding disorders; however, vaccination of patients with haemophilia requires comprehensive planning, taking into account disease severity, type and route of vaccination, and bleeding risk. Data also suggest vaccination timing does not need to take into consideration when the patient received factor VIII replacement.

Published
2019

4. PS1572 HEART DISEASE AND PANCREATIC IRON IN THALASSEMIA MAJOR

Author

Meloni, A., primary, Pistoia, L., additional, Spadola, V., additional, Murgia, M., additional, Quota, A., additional, Carrai, V., additional, Bulgarelli, S., additional, Mattei, R., additional, Pasin, M., additional, Sardella, L., additional, Restaino, G., additional, Preziosi, P., additional, Positano, V., additional, and Pepe, A., additional

Published
2019
Full Text
View/download PDF

7. PEG INTRON IN ESSENTIAL THROMBOCYTHAEMIA: TWO YEARS TREATAMENT EVALUTATION

Author

GUGLIOTTA L., BULGARELLI S., VIANELLI N., R.U.S.S.O.D., GAMBERI B., CANDONI A., MICHELUTTI T., IMOVILLI A., RUPOLI S., BARULLI S., TASSETTI A., LATAGLIATA R., FRATTARELLI N., SACCHI S., MONTANINI A., MAMMI C., CIANCIA R., ZANCHINI A., ZUMAGLINI F., DE BIASI E., BUCALOSSI A., GENTILI S., MAZZOTTA S., TABILIO A., MARCOMIGNI L., PASSAMONTI F., MALABARBA L., MIGLINO M., VALALDO R., GROSSI A., BALESTRI F., CACCIOLA E., CACCIOLA R., PISAPIA G., POGLIANI E., BONIFAZI F., FANIN R., LEONI P., MANDELLI F., ROTOLI B., ZACCARIA A., LAURIA F., MARTELLI M., LAZZARINO M., GOBBI M., BOSI A., GIUSTOLISI R., MAZZA P., BONVINI L., PISARRA P., FINCATO G., BACCARANI M., MARTINELLI, VINCENZO, Gugliotta, L., Bulgarelli, S., Vianelli, N., R. U. S. S. O., D., Gamberi, B., Candoni, A., Michelutti, T., Imovilli, A., Rupoli, S., Barulli, S., Tassetti, A., Latagliata, R., Frattarelli, N., Sacchi, S., Montanini, A., Mammi, C., Martinelli, Vincenzo, Ciancia, R., Zanchini, A., Zumaglini, F., DE BIASI, E., Bucalossi, A., Gentili, S., Mazzotta, S., Tabilio, A., Marcomigni, L., Passamonti, F., Malabarba, L., Miglino, M., Valaldo, R., Grossi, A., Balestri, F., Cacciola, E., Cacciola, R., Pisapia, G., Pogliani, E., Bonifazi, F., Fanin, R., Leoni, P., Mandelli, F., Rotoli, B., Zaccaria, A., Lauria, F., Martelli, M., Lazzarino, M., Gobbi, M., Bosi, A., Giustolisi, R., Mazza, P., Bonvini, L., Pisarra, P., Fincato, G., and Baccarani, M.

Abstract

Comunicazione orale Haemathologica, (abstract) vol 88 (suppl) n.ro 15

Published
2003

8. Anagrelide in Essential Thrombocythemia: a retrospettive study'

Author

GUGLIOTTA L., GROSSI A., MAZZUCCONI M. G., BULGARELLI S., BEGGI C., LISO V., SPECCHIOA G., COSER P., AMATO, BRUNO, ANGELUCCI E., DI TUCCI A., SCIORIO A., GIUSTOLISI R., CACCIOLA E., CACCIOLA R., IULIANO F., GIORDANO M., BOSI A., BALESTRI F., GHIO R., BALLEARI E., SPRIANO M., SACCHI S., MARCHESELLI R., ROTOLI B., CIANCIA R., GAIDANO G., CONCONI A., RIZZOLI V., CRUGNOLA M., TRINGALI S., BALDUINI C., NORIS P., MARTELLI M., TABILIO A., LIBERATI A. M., GERMANI A., ANDRIANI A., LAURIA F., GENTILI S., CARELLA A. M., SCALZULLI P. R., BOCCADORO M., CIOCCA VASINO A., FANIN R., CANDONI A., PIZZOLO G., AMBROSETTI A., ZANOTTI R., COMUNICAZIONE ORALE, HAEMATHOLOGICA, ABSTRACT VOL SUPPL N. RO, PAG, OTTOBRE, AMATO B., MARTINELLI, VINCENZO, Gugliotta, L., Grossi, A., Mazzucconi, M. G., Bulgarelli, S., Beggi, C., Liso, V., Specchioa, G., Coser, P., Amato, Bruno, Angelucci, E., DI TUCCI, A., Sciorio, A., Giustolisi, R., Cacciola, E., Cacciola, R., Iuliano, F., Giordano, M., Bosi, A., Balestri, F., Ghio, R., Balleari, E., Spriano, M., Sacchi, S., Marcheselli, R., Rotoli, B., Martinelli, Vincenzo, Ciancia, R., Gaidano, G., Conconi, A., Rizzoli, V., Crugnola, M., Tringali, S., Balduini, C., Noris, P., Martelli, M., Tabilio, A., Liberati, A. M., Germani, A., Andriani, A., Lauria, F., Gentili, S., Carella, A. M., Scalzulli, P. R., Boccadoro, M., CIOCCA VASINO, A., Fanin, R., Candoni, A., Pizzolo, G., Ambrosetti, A., Zanotti, R., Comunicazione, Orale, Haemathologica, ABSTRACT VOL SUPPL N., Ro, Pag, Ottobre, and Amato, B.

Abstract

COMUNICAZIONE ORALE HAEMATHOLOGICA, (ABSTRACT) VOL 88 (SUPPL) N.RO 15

Published
2003

11. Anagrelide treatment and cardiovascular evaluation in 130 patients with essential thrombocythemia (ET): Preliminary report of the Registro Italiano Trombocitemia (RIT)

Author

Gugliotta, L., Tieghi, A., Bulgarelli, S., Tortorella, C., Ciancia, R., Scalzulli, Pr, Cacciola, E., Cacciola, R., Rossi, D., Usala, E., Crugnola, M., Candoni, A., Giordano M, Andriani A., Santoro, Cristina, Vimercati, R., Liberati, M., Sciorio A., Specchia G., Martinelli, V., Gaidano, G., and Mazzucconi, Maria Gabriella

Published
2005

13. Anagrelide treatment and cardiovascular evaluation in 130 patients with assential trombo-cythemia (ET): preliminary report of the Registro Italiano Trombocitemia (RIT)

Author

Luigi, Gugliotta, Tieghi, A., Bulgarelli, S., Tortorella, G., Ciancia, R., Scalzulli, P. R., Cacciola, E, Cacciola, Rossella Rosaria, Rossi, D., Usala, E., Prugnola, M., Candoni, A., Giordano, M., Andrani, A., Santoro, C., Vimercati, R., Liberati, M., Sciorio, A., Specchia, G., MARTI NELLI, V., Gaidano, G., and Nazzucconi, M. G.

Published
2005

14. Bone Marrow evaluation according to the PVSG and WHO criteria in 90 essential thrombocythemia (ET) patients treated with PEG interferon alpha-2b. Preliminary results

Author

Luigi, Gugliotta, Bulgarelli, S., Asioli, S., Tieghi, A., Gardini, G., Sabattini, E., Franco, V., Boveri, E., Kvasnicka, H. M., Vinelli, N., Candoni, A., LA TAGLIATA, R., Passamonti, F., Rupoli, S, Martinelli, V., Zaccaria, A., Lauria, F., DE BIASI, E., Sacchi, S., Gobbi, M., Tabi, A., Lio, Cacciola, E., Cacciola, Rossella Rosaria, Grossi, A., Mazza, P., Bonifazi, F., Favoni, P., Mandelli, F., Baccarani, M, and Thiele, J.

Published
2005

15. PEG Intron treatment in 90 patients with assential thrombocithemia (ET) final report of a phase II study

Author

Luigi, Gugliotta, Bulgarelli, S., Vinelli, N., Russo, D., Candoni, A., Rupoli, S., LA TAGLIATA, R., Sacchi, S., Martinelli, V., DE BIASI, E., Bucalossi, A., Mazzotta, S., Tabilio, A., Passamonti, F., Grossi, A., Cacciola, Emma, Cacciola, R., Pogliani, E., Bonifazi, F., Fanin, R., Leoni, P., Mandelli, F., Zaccaria, A., Lauria, F., Lazzarino, M., Gobbi, M., Bosi, A., Mazza, P., Fincato, G., Favoni, P., and Baccarani, M

Published
2005

17. Anagrelide in essential thrombocythemia: a retrospective analysis of 220 patients

Author

Gugliotta, L., Grossi, A., Mazzucconi, M. G., Bulgarelli, S., Gamberi, B., Imovilli, A., Ba, F., Lestri, Liso, V., Specchia, G., Scalzulli, P. R., Liberati, A. M., Bassetti, A., Angelucci, E., A, Tucci, Di, Iuliano, F., Gaidano, G., Conconi, A. R., Cacciola, E., Cacciola, Rossella Rosaria, Spriano, M., Prugnola, M., Tabilio, A., Balduini, C., Noris, P., Amato, B., Candoni, A., Balleari, E., Sacchi, S, Ambrosetti, A., Canotti, R., Giordano, M., Andriani, A., Sciorino, A., Ciocca, A., Vasino, Martinelli, V., Ciancia, R., Tringali, S., and Lauria, F.

Published
2003

18. Anagrelide in assential thronbocythemia: a retrospective study

Author

Gugliotta, L, Grossi, A, Mazzucconi, Mg, Bulgarelli, S, Beggi, C, Liso, V, Specchia, G, Coser, P, Amato, B, Angelucci, E, Di Tucci, A, Sciorino, A, Giustolisi, R, Cacciola, Emma, Cacciola, Rossella Rosaria, Iuliano, F, Giordano, M, Bosi, A, Balestri, F, Ghio, R, Balleari, E, Spriano, M, Sacchi, S, Marcheselli, R, Rotoli, B, Martinelli, V, Ciancia, R, Gaidano, G, Conconi, A, Rizzoli, V, Prugnola, M, Trincali, S, Balduini, C, Noris, P, Martelli, M, Tabilio, A, Liberati, Am, Germani, A, Andriani, A, Lauria, F, Gentili, S, Carella, Am, Scalzulli, Pr, Boccadoro, M, Ciocca Vasino, A, Fanin, R, Candoni, A, Pizzolo, G, Ambrosetti, A, and Canotti, R.

Published
2003

19. Anagrelide treatment in 167 patients with essential thrombocythaemia : a retrospective study of the Italian Group GIMMC

Author

Gugliotta, L., Grossi, A., Mazzucconi, M. G., Beggi, C, Bulgarelli, S, Redi, R, Balestri, F, Scalzulli, P. R, Noris, P, Liberati, A. M., Spriano, M, Tabilio, A, Amato, B, DI TUCCI, A, Candoni, A, Iuliano, F, Balleari, E, Sacchi, S, Gaidano, G, Giordano, M, Sciorino, A, Specchia, G, Andriani, A, Cacciola, Emma, Cacciola, Rossella Rosaria, Martinelli, V, Tringali, S, Lauria, F, CIOCCA VASINO, A, and Prugnola, M.

Published
2003

20. PEG-Intron in essential thrombocythaemia: two years treatment evaluation

Author

Gugliotta, L, Bulgarelli, S, Vianelli, N, Russo, D, Gamberi, B, Candoni, A, Michelutti, T, Imovilli, A, Rupoli, S, Barulli, S, Tassetti, A, Latagliata, R, Frattarelli, N, Sacchi, S, Montani, Ni, A, Mammi, C, Martinelli, V, Ciancia, R, Zanchini, A, Zumaglini, F, DE BIASI, E, Bucalos, Si, A, Gentili, S, Mazzotta, S, Tabilio, A, Marcomigni, L, Passamonti, F, Malabarba, L, Migli, No, M, Varaldo, R, Grossi, A, Balestri, F, Cacciola, Emma, Cacciola, Rossella Rosaria, Pisapia, G, Pogliani, E, Bonifazi, F, Fanin, R, Leoni, P, Mandelli, F, Rotoli, B, Zaccaria, A, Lauria, F, Martelli, M, Lazzarino, M, Gobbi, M, Bosi, A, Giustolisi, R, Mazza, P, Bovini, L, Pisarra, P, Fincato, G, and Baccarani, M.

Published
2003

21. Anagrelide treatment in 167 patients with assential thrombocythaemia: a retrospective study of the Italian Group GIMMC

Author

Gugliotta, L., Grossi, A., Mazzucconi, M. G., Beggi, C., Bulgarelli, S., Redi, R., Balestri, F., Scalzulli, P. R., Noris, P., Liberati, A. M., Spriano, M., Tabilio, A., Amato, B., DI TUCCI, A., Candoni, A., Iuliano, F., Balleari, E., Sacchi, S., Gaidano, G., Giordano, M., Sciorino, A., Specchia, G, Andriani, A., Cacciola, E., Cacciola, Rossella Rosaria, Martinelli, V., Trincali, S., Lauria, F., A, Ciocca, Vasino, and Prugnola, M.

Published
2003

22. PEG Intron in essential thrombocythemai: two years tretament in 90 patients

Author

Gugliotta, L., Bulgarelli, S., Vinelli, N., Russo, D., Candoni, A., Michelutti, T., Ruoli, S., Barulli, S., Latagliata, R., Sacchi, S., Martinelli, V., Ciancia, R., Zumaglini, F., DE BIASI, E., Bucalossi, A., Mazzotta, S., Tabilio, A., Marcomigni, L., Passamonti, F., Malabarba, L., Miglino, M, Varaldo, R., Balestri, F., Grossi, A., Cacciola, E., Cacciola, Rossella Rosaria, Pisapia, G., Boni, F., Fazi, Fanin, R., Leoni, P., Mandelli, F., Rotoli, B., Zaccaria, A., Lauria, F., Martinelli, M., Lazzarino, M, Gobbi, M., Bosi, A., Giustolisi, R., Mazza, P., Fincato, G., and Baccarani, M.

Published
2003

23. Peg Interferon a- 2b (Peg Intron) in essential Thrombocythemia

Author

Gugliotta, L, Bulgarelli, S, Vinelli, N, Russo, D, Gamberi, B, Candoni, A, Ruoli, S, Barulli, S, Latagliata, R, Frattarelli, N, Sacchi, S, Serbano, S, Martinelli, V, Ciancia, R, Molinari, A. L, DE BIASI, E, Bucalossi, A, Tabilio, A, Marcomigni, L, Passamonti, F, Miglino, M, Varaldo, R, Grossi, A, Cacciola, Emma, Cacciola, Rossella Rosaria, Pisapia, G, Gentili, S, Pogliani, E, Fincato, G, Baccarani, M., L., Gugliotta, S., Bulgarelli, N., Vianelli, D., Russo, B., Gamberi, A., Candoni, S., Rupoli, S., Barulli, R., Latagliata, N., Frattarelli, S., Sacchi, S., Nerbano, Martinelli, Vincenzo, R., Ciancia, A. L., Molinari, E., DE BIASI, A., Bucalossi, A., Tabilio, L., Marcamigni, F., Passamonti, M., Miglino, R., Varaldo, A., Grossi, E., Cacciola, R., Cacciola, G., Pisapia, S., Gentili, E., Pogliani, G., Fincato, and M., Baccarani

Abstract

BLOOD, VOL 100 N.RO 11

Published
2002

24. PEG Interferon alpha2b (PEG Intron) in Essential Thrombocytemia: Phase II Study for Determination of the Minimun Effective, Safe and Tolerated Dose. Preliminary Data

Author

Gugliotta, L., Russo, D., Vianelli, N., Caglio, S., Bulgarelli, S., Gamberi, B., Candoni, A., Martinelli, V., Latagliate, R., Rupoli, S. Zaccaria A., Sacchi, Stefano, De Biasi, E., Passamonti, F., Miglino, M., Gentili, S., Tabilio, A., Grossi, A., Cacciola, E., Pogliani, E., and Finc

Subjects
PEG Interferon alpha2b
Published
2001

25. Peg-Interferon -2b in essential thrombocythemia: phase II study for de- termination of the minimum effective, safe and tolerated dose. Prelimina- ry data

Author

Gugliotta, L, Russo, D, Bulgarelli, S, Vianelli, N, Caglio, S, Martinelli, V, Sacchi, S, Rupoli, S, Passamonti, F, Bucalossi, A, De Biasi, E, Cacciola, Rossella Rosaria, Cacciola, Emma, Candoni, A, Valdrè, L, Ciancia, R, Barulli, L, Agostini, V, Finazzi, G, Latagliata, R, Tabilio, A, Marcomigni, L, Miglino, M, Palazzo, G, Molinari, A, Grossi, A, Mazzucconi, Mg, Gobbi, M, Martelli, M, Zaccaria, A, Mazza, P, Boccadoro, M, Giustolisi, R, Lauria, F, Lazzarino, M, Leoni, P, Rotoli, B, Fanin, R, Rossi Ferrini PL, Barbui, T, Mandelli, F, Fincato, G, and Baccarani, M.

Published
2001

38. Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results.

Author

Gugliotta, Luigi, primary, Bulgarelli, S., primary, Asioli, S., primary, Tieghi, A., primary, Gardini, G., primary, Sabattini, E., primary, Franco, V., primary, Boveri, E., primary, Kvasnicka, H. M., primary, Vianelli, N., primary, Candoni, A., primary, Latagliata, R., primary, Passamonti, F., primary, Rupoli, S., primary, Martinelli, V., primary, Zaccaria, A., primary, Lauria, F., primary, De Biasi, E., primary, Sacchi, S., primary, Gobbi, M., primary, Tabilio, A., primary, Cacciola, E., primary, Cacciola, R., primary, Grossi, A., primary, Mazza, P., primary, Bonifazi, F., primary, Favini, P., primary, Mandelli, F., primary, Baccarani, M., primary, and Thiele, J., primary

Published
2005
Full Text
View/download PDF

39. Anagrelide Treatment and Cardiovascular Evaluation in 130 Patients with Essential Thrombocythemia (ET): Preliminary Report of the Registro Italiano Trombocitemia (RIT).

Author

Gugliotta, Luigi, primary, Tieghi, A., primary, Bulgarelli, S., primary, Tortorella, G., primary, Ciancia, R., primary, Scalzulli, P. R., primary, Cacciola, E., primary, Cacciola, R., primary, Rossi, D., primary, Usala, E., primary, Crugnola, M., primary, Candoni, A., primary, Giordano, M., primary, Andriani, A., primary, Santoro, C., primary, Vimercati, R., primary, Liberati, M., primary, Sciorio, A., primary, Specchia, G., primary, Martinelli, V., primary, Gaidano, G., primary, and Mazzucconi, M. G., primary

Published
2005
Full Text
View/download PDF

40. PEG Intron Treatment in 90 Patients with Essential Thrombocythemia (ET) Final Report of a Phase II Study.

Author

Gugliotta, Luigi, primary, Bulgarelli, S., additional, Vianelli, N., additional, Russo, D., additional, Candoni, A., additional, Rupoli, S., additional, Latagliata, R., additional, Sacchi, S., additional, Martinelli, V., additional, De Biasi, E., additional, Bucalossi, A., additional, Mazzotta, S., additional, Tabilio, A., additional, Passamonti, F., additional, Grossi, A., additional, Cacciola, E., additional, Cacciola, R., additional, Pogliani, E., additional, Bonifazi, F., additional, Fanin, R., additional, Leoni, P., additional, Mandelli, F., additional, Zaccaria, A., additional, Lauria, F., additional, Lazzarino, M., additional, Gobbi, M., additional, Bosi, A., additional, Mazza, P., additional, Fincato, G., additional, Favini, P., additional, and Baccarani, M., additional

Published
2005
Full Text
View/download PDF

41. Bone Marrow Biopsy and Aspirate Evaluation in 90 Patients with Essential Thrombocythemia Treated with PEG Interferon alpha-2b. Preliminary Results.

Author

Gugliotta, L., primary, Bulgarelli, S., additional, Tieghi, A., additional, Asioli, S., additional, Gardini, G., additional, Vianelli, N., additional, Candoni, A., additional, Latagliata, R., additional, Rupoli, S., additional, Martinelli, V., additional, Zaccaria, A., additional, De Biasi, E., additional, Sacchi, S., additional, Lauria, F., additional, Miglino, M., additional, Passamonti, F., additional, Tabilio, A., additional, Cacciola, E., additional, Grossi, A., additional, Pisapia, G., additional, Favini, P., additional, and Baccarani, M., additional

Published
2004
Full Text
View/download PDF

46. Anagrelide in essential thrombocythemia: A retrospective analysis of 220 patients

Author

Gugliotta, L., Grossi, A., Mazzucconi, Mg, Bulgarelli, S., Gamberi, B., Annalisa Imovilli, Balestri, F., Liso, V., Specchia, G., Scalzulli, Pr, Liberati, Am, Bassetti, A., Angelucci, E., Di Tucci, A., Iuliano, F., Gaidano, G., Conconi, Ar, Cacciola, E., Cacciola, R., Spriano, M., Crugnola, M., Tabilio, A., Balduini, C., Noris, P., Amato, B., Candoni, A., Balleari, E., Sacchi, S., Ambrosetti, A., Zanotti, R., Giordano, M., Andriani, A., Sciorio, A., Vasino, Ac, Martinelli, V., Ciancia, R., Tringali, S., and Lauria, F.

47. Peg Interferon alpha-2b (Peg Intron) in Essential Thrombocythemia

Author

Gugliotta, L., Bulgarelli, S., Vianelli, N., Russo, D., Gamberi, B., Candoni, A., Rupoli, S., Barulli, S., Latagliata, R., Frattarelli, N., Sacchi, S., Nerbano, S., Martinelli, V., Ciancia, R., Molinari, Al, Biasi, E., Bucalossi, A., Tabilio, A., Marcomigni, L., Passamonti, F., Miglino, M., Riccardo Varaldo, Grossi, A., Cacciola, E., Cacciola, R., Pisapia, G., Gentili, S., Pogliani, E., Fincato, G., and Baccarani, M.

Subjects
Thrombocythemia Interferon Peg Intron [Keywords]

49. Bone Marrow Biopsy and Aspirate Evaluation in 90 Patients with Essential Thrombocythemia Treated with PEG Interferon alpha-2b. Preliminary Results

Author

Alfonso Zaccaria, Francesco Passamonti, Simona Bulgarelli, E. De Biasi, Vincenzo Martinelli, Emma Cacciola, Antonio Tabilio, Anna Candoni, Alessia Tieghi, Alberto Grossi, P. Favini, Roberto Latagliata, Silvia Asioli, Stefano Sacchi, Michele Baccarani, Maurizio Miglino, Luigi Gugliotta, Nicola Vianelli, Serena Rupoli, G. Gardini, Francesco Lauria, G. Pisapia, Gugliotta, L., Bulgarelli, S., Tieghi, A., Asioli, S., Gardini, G., Vianelli, N., Candoni, A., Latagliata, R., Rupoli, S., Martinelli, Vincenzo, Zaccaria, A., DE BIASI, E., Sacchi, S., Lauria, F., Miglino, M., Passamonti, F., Tabilio, A., Cacciola, E., Grossi, A., Pisapia, G., Favini, P., and Baccarani, M.

Subjects
medicine.medical_specialty, medicine.diagnostic_test, Essential thrombocythemia, business.industry, Immunology, Cell Biology, Hematology, medicine.disease, Biochemistry, Gastroenterology, Granulopoiesis, Surgery, medicine.anatomical_structure, Tolerability, Fibrosis, Internal medicine, PEG ratio, Biopsy, medicine, Platelet, nd, Bone marrow, business
Abstract

Ninety patients with Essential Thrombocythemia (ET) where object of a phase II prospective multicentre study designed to evaluate efficacy, safety and tolerability of a two years treatment with PEG Interferon α-2b (PEG Intron, Schering Plough). The patients, 30 M and 60 F, 18–72 years old (median 45), observed in 16 Hematological Institutions of the Gruppo Italiano Malattie Mieloproliferative Croniche (GIMMC), received the ET diagnosis according to the PVSG criteria. At PEG Intron treatment start the patients showed: previous cytoreduction 97% (IFN α 31%), platelet count >1000 x 109/L 81%, splenomegaly 22%. At the end of the first year The PEG Intron starting dose of 25 μg/week resulted increased to a mean value of 55 μg/week and the Hematological Response (HR = Plts 45 years, platelet count >1000 x109/L, Hb 50 μg/week. In conclusion, the present study shows that in ET patients a two years PEG Intron treatment, able to induce and to maintain the Hematological Response in the majority of cases, is associated to a decrease of bone marrow cellularity, granulopoiesis, erytropoiesis, MK number, size and ploidy and, moreover, with an increase of MK dystrophy and of bone marrow fibrosis. These preliminary data on bone biopsy and aspirate will be object of a planned centralized reevaluation by a Panel of Pathologists and Clinicians.

Published
2004
Full Text
View/download PDF

50. Bone marrow evaluation according to the PVSG and WHO criteria in 90 essential thrombocythemia (ET) patients treated with PEG interferon alpha-2b. Preliminary results

Author

Emanuela Boveri, Marco Gobbi, S. Bulgarelli, R. Cacciola, Luigi Gugliotta, Vincenzo Martinelli, Franco Mandelli, F. Lauria, Patrizio Mazza, Juergen Thiele, Alberto Grossi, Silvia Asioli, Nicola Vianelli, Stefano Sacchi, Emma Cacciola, Anna Candoni, Michele Baccarani, Alessia Tieghi, F Bonifazi, G. Gardini, E. De Biasi, Alfonso Zaccaria, P. Favini, Serena Rupoli, Antonio Tabilio, Roberto Latagliata, Elena Sabattini, Hans-Michael Kvasnicka, Francesco Passamonti, Vito Franco, GUGLIOTTA L, BULGARELLI S, ASIOLI S, TIEGHI A, GARDINI G, SABATTINI E, FRANCO V, BOVERI E, KVASNICKA HM, VIANELLI N, CANDONI A, LATAGLIATA R, PASSAMONTI F, RUPOLI S, MARTINELLI V, ZACCARIA A, LAURIA F, DE BIASI E, SACCHI S, GOBBI M, TABILIO A, CACCIOLA E, CACCIOLA R, GROSSI A, MAZZA P, BONIFAZI F, FAVINI P, MANDELLI F, BACCARANI M, and THIELE J

Subjects
medicine.medical_specialty, thrombocythemia (ET) patients, Immunology, Essential Thrombocythemia (ET), PEG Interferon alpha-2b, Phases of clinical research, Alpha (ethology), Biochemistry, Gastroenterology, Fibrosis, Internal medicine, PEG ratio, Biopsy, Medicine, medicine.diagnostic_test, business.industry, Essential thrombocythemia, Cell Biology, Hematology, medicine.disease, Surgery, medicine.anatomical_structure, Tolerability, Bone marrow evaluation, Bone marrow, business
Abstract

Ninety ET patients diagnosed according to the PVSG criteria were enrolled in a phase II study (sponsored by the Schering-Plough Company) designed to evaluate the efficacy, safety and tolerability of a two years treatment with PEG Interferon alpha-2 b (PEG Intron). The patients, observed in 16 Italian Centres belonging to the GIMEMA Cooperative Group and judged at high risk, had been previously treated with cytoreductive (97%) and antiplatelet (91%) drugs. At the study start the patients, 60 F and 30 M, mean age 45 years, showed splenomegaly in 22% of cases. The Hematological Response (HR: PLT

Catalog

Books, media, physical & digital resources
See catalog results